Literature DB >> 19821490

Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma.

Helena Nord1, Ulrika Segersten, Johanna Sandgren, Kenneth Wester, Christer Busch, Uwe Menzel, Jan Komorowski, Jan P Dumanski, Per-Uno Malmström, Teresita Díaz de Ståhl.   

Abstract

Urinary bladder cancer is a heterogeneous disease with tumors ranging from papillary noninvasive (stage Ta) to solid muscle infiltrating tumors (stage T2+). The risk of progression and death for the most frequent diagnosed type, Ta, is low, but the high incidence of recurrences has a significant effect on the patients' quality of life and poses substantial costs for health care systems. Consequently, the purpose of this study was to search for predictive factors of recurrence on the basis of genetic profiling. A clinically well characterized cohort of Ta bladder carcinomas, selected by the presence or absence of recurrences, was evaluated by an integrated analysis of DNA copy number changes and gene expression (clone-based 32K, respectively, U133Plus2.0 arrays). Only a few chromosomal aberrations have previously been defined in superficial bladder cancer. Surprisingly, the profiling of Ta tumors with a high-resolution array showed that DNA copy alterations are relatively common in this tumor type. Furthermore, we observed an overrepresentation of focal amplifications within high-grade and recurrent cases. Known (FGFR3, CCND1, MYC, MDM2) and novel candidate genes were identified within the loci. For example, MYBL2, a nuclear transcription factor involved in cell-cycle progression; YWHAB, an antiapoptotic protein; and SDC4, an important component of focal adhesions represent interesting candidates detected within two amplicons on chromosome 20, for which DNA amplification correlated with transcript up-regulation. The observed overrepresentation of amplicons within high-grade and recurrent cases may be clinically useful for the identification of patients who will benefit from a more aggressive therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19821490     DOI: 10.1002/ijc.24954

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

Review 1.  FGF receptor inhibitors: role in cancer therapy.

Authors:  Gennaro Daniele; Jesus Corral; L Rhoda Molife; Johann S de Bono
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

2.  Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis.

Authors:  Carolyn D Hurst; Fiona M Platt; Claire F Taylor; Margaret A Knowles
Journal:  Clin Cancer Res       Date:  2012-08-29       Impact factor: 12.531

Review 3.  Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.

Authors:  Margaret A Knowles; Carolyn D Hurst
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

4.  Novel amplifications in pediatric medulloblastoma identified by genome-wide copy number profiling.

Authors:  Helena Nord; Susan Pfeifer; Pelle Nilsson; Johanna Sandgren; Svetlana Popova; Bo Strömberg; Irina Alafuzoff; Monica Nistér; Teresita Díaz de Ståhl
Journal:  J Neurooncol       Date:  2011-10-07       Impact factor: 4.130

5.  Cell-Free DNA Integrity Analysis in Urine Samples.

Authors:  Valentina Casadio; Samanta Salvi; Filippo Martignano; Roberta Gunelli; Sara Ravaioli; Daniele Calistri
Journal:  J Vis Exp       Date:  2017-01-05       Impact factor: 1.355

Review 6.  Fibroblast growth factor signalling: from development to cancer.

Authors:  Nicholas Turner; Richard Grose
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

7.  Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer.

Authors:  Hideaki Murase; Mikito Inokuchi; Yoko Takagi; Keiji Kato; Kazuyuki Kojima; Kenichi Sugihara
Journal:  Mol Clin Oncol       Date:  2014-05-15

8.  FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer.

Authors:  Yann Neuzillet; Bas W G van Rhijn; Nadia L Prigoda; Bharati Bapat; Liyang Liu; Peter J Bostrom; Neil E Fleshner; Brenda L Gallie; Alexandre R Zlotta; Michael A S Jewett; Theo H van der Kwast
Journal:  Virchows Arch       Date:  2014-06-01       Impact factor: 4.064

9.  Nuclear translocation of fibroblast growth factor receptor 3 and its significance in pancreatic cancer.

Authors:  Li Zhou; Lu-Tian Yao; Zhi-Yong Liang; Wei-Xun Zhou; Lei You; Qian-Qian Shao; Shuai Huang; Jun-Chao Guo; Yu-Pei Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 10.  FGF/FGFR signaling in health and disease.

Authors:  Yangli Xie; Nan Su; Jing Yang; Qiaoyan Tan; Shuo Huang; Min Jin; Zhenhong Ni; Bin Zhang; Dali Zhang; Fengtao Luo; Hangang Chen; Xianding Sun; Jian Q Feng; Huabing Qi; Lin Chen
Journal:  Signal Transduct Target Ther       Date:  2020-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.